Pinocembrin, a compound isolated from eucalyptus trees, significantly reduced the signs and symptoms of lung damage in a sheep model of pulmonary fibrosis (PF), a study demonstrated. “We found that pinocembrin improved lung function, attenuated [eased the effect of] lung inflammation, and decreased overall pathology scores compared to damaged…
AstraZeneca has added a novel target for idiopathic pulmonary fibrosis (IPF) to its portfolio, which was uncovered using BenevolentAI’s artificial intelligence-driven medication discovery platform. “The cause of IPF is largely unknown and the exact mechanisms involved in the progression of IPF remain elusive,” Anne Phelan, PhD, chief scientific…
A lyric-writing challenge has culminated in a new song, “Breath of Life (Para Don Berna),” that is being debuted by “American Idol” winner Jordin Sparks and New York Yankees veteran and Latin Grammy nominee Bernie Williams to increase awareness and promote the early diagnosis of idiopathic pulmonary fibrosis (IPF).
An autoantibody reduction regimen that combines three treatments improved lung function and survival in adults with idiopathic pulmonary fibrosis (IPF) who are experiencing acute symptom worsening, a small study suggests. Early, positive clinical responses predicted better long-term outcomes, and high levels of autoantibodies against epithelial markers before treatment were…
AdAlta announced that AD-214, its candidate treatment for idiopathic pulmonary fibrosis (IPF), has been successfully made into an aerosol for inhalation — a nebulized form — while retaining the molecular properties that supported its potential effectiveness in preclinical studies. “The results of these studies support AD-214 being delivered by…
Some people with so-called “long COVID” — breathlessness and other respiratory symptoms that persist long after the acute phase of COVID-19 infection — may have had undiagnosed pulmonary fibrosis before they contracted the infection. Scientists at University of Michigan Health reported these findings in the study, “…
Pulmonary rehabilitation is as effective a treatment for idiopathic pulmonary fibrosis (IPF) as it is for chronic obstructive pulmonary disease (COPD), a real-world study found. “Patients with IPF have similar completion rates and magnitude of response to pulmonary rehabilitation [to patients with COPD],” its scientists wrote. “These data reinforce the…
The levels of a cancer-suppressing molecule called microRNA-326 (miR-326) are reduced significantly in the lungs of a mouse model of silica-induced pulmonary fibrosis (PF), a study shows. Increasing the levels of miR-326 in these mice lessened lung scarring (fibrosis) and suppressed the production of pro-fibrotic molecules, highlighting miR-326 as a…
The first healthy volunteer has been dosed in a trial evaluating ISM001-055, Insilico Medicine’s artificial intelligence (AI)-discovered therapy candidate for idiopathic pulmonary fibrosis (IPF). “We are very pleased to see Insilico Medicine’s first antifibrotic [treatment] candidate entering into the clinic,” Feng Ren, PhD, Insilico’s chief strategy officer, said…
Cudetaxestat (BLD-0409), an investigational therapy for idiopathic pulmonary fibrosis (IPF), showed favorable safety and tolerability in a Phase 1 trial of healthy volunteers. Developed by Blade Therapeutics, cudetaxestat is designed to block the activity of an enzyme called autotaxin that produces a pro-scarring (fibrotic) signaling molecule. This enzyme commonly…
Get regular updates to your inbox.
